-transparent.png){kind=logo}
Ketanserin, 40 mg b.i.d., or matching placebo were administered for 8 weeks each in a randomised double-blind crossover design to 23 patients with Raynaud's phenomenon. Ketanserin had no effect on Doppler arterial patency or blood flow at rest, 37 degrees C, 15 degrees C, or during recovery after cold challenge. Red cell deformability index and whole blood viscosity were not significantly affected by ketanserin treatment. In vivo bleeding time was prolonged on ketanserin (p less than 0.05) but beta-thromboglobulin and platelet factor 4 were unaffected. There was a nonsignificant decrease in platelet aggregation response to serotonin but no change at all with other aggregating agents on treatment with ketanserin.
J Longstaff, and
R Gush, and
E H Williams, and
M I Jayson
August 1990,
International journal of microcirculation, clinical and experimental,
J Longstaff, and
R Gush, and
E H Williams, and
M I Jayson
December 1990,
British journal of clinical pharmacology,
J Longstaff, and
R Gush, and
E H Williams, and
M I Jayson
January 1990,
European journal of clinical pharmacology,
J Longstaff, and
R Gush, and
E H Williams, and
M I Jayson
October 1984,
British medical journal (Clinical research ed.),
J Longstaff, and
R Gush, and
E H Williams, and
M I Jayson
December 1990,
Medicina clinica,
J Longstaff, and
R Gush, and
E H Williams, and
M I Jayson
June 1990,
Journal of cardiovascular pharmacology,
J Longstaff, and
R Gush, and
E H Williams, and
M I Jayson
December 1988,
British journal of rheumatology,
J Longstaff, and
R Gush, and
E H Williams, and
M I Jayson
January 1988,
European journal of clinical pharmacology,
J Longstaff, and
R Gush, and
E H Williams, and
M I Jayson
September 1989,
The American journal of medicine,
J Longstaff, and
R Gush, and
E H Williams, and
M I Jayson
September 1984,
British medical journal (Clinical research ed.),
